<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multiple myeloma: Staging and prognostic studies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multiple myeloma: Staging and prognostic studies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multiple myeloma: Staging and prognostic studies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacob P Laubach, MD, MPP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Plasma cell myeloma is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin and can present as a single lesion (solitary plasmacytoma) or multiple lesions (multiple myeloma [MM]). This clone of plasma cells proliferates in the bone marrow and often results in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or fractures. Additional disease-related complications include hypercalcemia, kidney impairment, anemia, and infections.</p><p>This topic review will discuss the staging and prognostic studies used in MM. The pathogenesis, clinical manifestations, diagnosis, and the different modalities used for therapy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology"</a>.)</p><p></p><p class="headingAnchor" id="H8178849"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>While multiple myeloma (MM) is considered an incurable form of cancer, patient outcomes continue to improve in terms of both the duration and quality of life [<a href="#rid1">1</a>]. With modern therapy, the median overall survival exceeds eight years, and varies from a few months in patients with ultra-high-risk features to more than 15 years in patients with lower risk features. In patients who are eligible for hematopoietic cell transplantation, median overall survival exceeds 12 years with standard risk myeloma and is over 6 years in high risk myeloma [<a href="#rid2">2,3</a>].</p><p>MM is a heterogeneous disease; some patients present with rapidly progressive symptoms and organ dysfunction whereas others have a more indolent clinical presentation  (<a class="graphic graphic_figure graphicRef99029" href="/d/graphic/99029.html" rel="external">figure 1</a>). The prognosis of patients with MM is dependent on four key factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Staging (disease characteristics)</p><p class="bulletIndent1"><span class="glyph">●</span>Patient factors (host characteristics)</p><p class="bulletIndent1"><span class="glyph">●</span>Disease biology (clinical characteristics, including plasmablastic morphology and the presence of extramedullary involvement)</p><p class="bulletIndent1"><span class="glyph">●</span>Availability and response to therapy </p><p></p><p>Of these four key factors, information on staging, patient factors, and disease biology can be identified by prognostic studies at the outset and are discussed in this topic. On the other hand, response to therapy can only be known after the patient has started therapy and is complicated by the fact that rapidity and completeness of the response may not always correlate with good long-term outcome. Most of the data regarding prognostic studies in patients with MM come from evaluations at the time of diagnosis. It is unclear how many of these factors may affect outcomes in previously treated patients. In addition, it is not clear how the prognostic value of these factors will change with the emergence of new therapies.</p><p>Prognostic studies have numerous benefits in both the clinical and research setting [<a href="#rid4">4</a>]. As examples, they:</p><p class="bulletIndent1"><span class="glyph">●</span>Provide the patient and physician with a better understanding of the aggressiveness of disease and chance of survival</p><p class="bulletIndent1"><span class="glyph">●</span>Lead to a better understanding of the patient population studied in a particular trial</p><p class="bulletIndent1"><span class="glyph">●</span>Allow for a gross comparison between patient populations in different trials</p><p class="bulletIndent1"><span class="glyph">●</span>May help guide therapy selection </p><p class="bulletIndent1"><span class="glyph">●</span>Identify new targets for therapy</p><p></p><p>An individual finding may be a prognostic marker, a predictive marker, or both [<a href="#rid5">5,6</a>]. Prognostic markers are associated with clinical outcomes independent of therapy received. Such markers usually reflect tumor burden, distribution, and growth rate. In contrast, predictive markers inform the likelihood of response to a given treatment and therefore impact choice of therapy. Such markers may be the target of the treatment or may modify the expression and/or function of the target. Identifying predictive markers will facilitate a move towards precision medicine, which uses genetic or molecular profiling to tailor therapy for the individual patient.</p><p class="headingAnchor" id="H2"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The Revised International Staging System (R-ISS)  (<a class="graphic graphic_table graphicRef132695" href="/d/graphic/132695.html" rel="external">table 1</a>) is the preferred staging system for MM. </p><p>The R-ISS has replaced earlier systems including Durie-Salmon  (<a class="graphic graphic_table graphicRef56890" href="/d/graphic/56890.html" rel="external">table 2</a>) [<a href="#rid7">7</a>], the International Staging System (ISS) [<a href="#rid8">8</a>], and the International Myeloma Working Group (IMWG)-2014 staging system [<a href="#rid9">9</a>]. </p><p>Staging systems are used to guide treatment decisions and to stratify patients enrolled in clinical trials and allow clinicians to better interpret data from such trials. They should be used only in patients with symptomatic, overt MM; they should not be used in patients with smoldering myeloma or monoclonal gammopathy of undetermined significance, since their value in such populations is not known. </p><p class="headingAnchor" id="H68873188"><span class="h2">Revised International Staging System (R-ISS)</span><span class="headingEndMark"> — </span>The R-ISS uses serum beta-2 microglobulin (B2M), serum albumin, serum lactate dehydrogenase (LDH), and bone marrow FISH results to stratify patients into three risk groups  (<a class="graphic graphic_table graphicRef132695" href="/d/graphic/132695.html" rel="external">table 1</a>). It provides more robust prognostic information than that from the original ISS which did not include information on LDH and FISH [<a href="#rid8">8</a>]. </p><p>R-ISS is calculated as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – B2M &lt;3.5 mg/L, serum albumin ≥3.5 g/dL, normal LDH, and no del(17p), t(4;14), or t(14;16) by FISH</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II – neither stage I nor stage III</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III – B2M ≥5.5 mg/L and elevated LDH - and/or - del(17p), t(4;14), or t(14;16) by FISH</p><p></p><p>The R-ISS was developed based on 3060 patients with newly diagnosed MM enrolled onto one of 11 international trials [<a href="#rid10">10</a>]. Treatment included autologous hematopoietic cell transplantation (65 percent), immunomodulatory agents (66 percent), and proteasome inhibitors (44 percent). Patients were stratified into three risk groups with significantly different estimated rates of overall survival (OS) and progression-free survival (PFS) at five years  (<a class="graphic graphic_figure graphicRef105116" href="/d/graphic/105116.html" rel="external">figure 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>R-ISS I (n = 871) – Estimated OS and PFS at five years were 82 and 55 percent, respectively. Median OS was not reached. Median PFS was 66 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>R-ISS II (n = 1894) – Estimated OS and PFS at five years were 62 and 36 percent, respectively. Median OS and PFS were 83 and 42 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>R-ISS III (n = 295) – Estimated OS and PFS at five years were 40 and 24 percent, respectively. Median OS and PFS were 43 and 29 months.</p><p></p><p>On subset analysis, the R-ISS provided prognostic value independent of patient age and therapy received. The R-ISS has been validated in several separate cohorts using different treatment approaches [<a href="#rid11">11-13</a>]. </p><p class="headingAnchor" id="H472725695"><span class="h1">CYTOGENETIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Fluorescence in situ hybridization (FISH) is performed at time of initial diagnosis to help determine the revised International Staging System (R-ISS) stage and to guide therapy  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 1</a>). Metaphase cytogenetics have long been a mainstay of the diagnostic evaluation for patients with MM. However, the sensitivity of metaphase cytogenetics is limited in comparison to FISH, and thus the approach has less overall utility. Next-generation sequencing techniques are being evaluated and hold promise as a diagnostic tool in myeloma management as well. At present, we rely primarily upon FISH for prognostic purposes. (See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Risk stratification'</a> and <a class="local">'Revised International Staging System (R-ISS)'</a> above.)</p><p>Patients with t(4;14), t(14;16), t(14;20), del17p13, or gain 1q by FISH account for approximately 25 percent of MM and have a shortened median survival with standard therapy [<a href="#rid14">14,15</a>]. Due to their prognostic value and the widespread availability of probes for FISH testing, t(4;14), t(14;16), and del17p are considered high-risk cytogenetics in the R-ISS [<a href="#rid10">10</a>]. (See <a class="local">'Specific IgH translocations'</a> below and <a class="local">'Del(17p)'</a> below.)</p><p>While deletion 13 and hypodiploidy have been considered adverse prognostic factors when detected by conventional cytogenetics, these are not independent predictors of poor outcome when detected by FISH [<a href="#rid16">16</a>]. </p><p>The most widely used preferred method for detecting cytogenetic abnormalities in MM is through interphase FISH studies on bone marrow plasma cells [<a href="#rid4">4,17,18</a>]. The preferred FISH techniques are either interphase FISH in purified plasma cells or light chain-restricted plasma cell cytoplasmic immunoglobulin enhanced FISH [<a href="#rid4">4</a>]. A more advanced and sensitive alternative to FISH is next-generation sequencing methods such as RNAseq, but these are not widely available. These tests also maintain sensitivity in the context of hemodilution of the bone marrow aspirate sample.</p><p>Using FISH, MM can be molecularly classified into unique cytogenetic entities  (<a class="graphic graphic_table graphicRef83079" href="/d/graphic/83079.html" rel="external">table 3</a>) [<a href="#rid4">4,15,19</a>]. Some cytogenetic subtypes, such as t(11;14) and t(6;14) and trisomies of odd numbered chromosomes, are considered to indicate standard-risk myeloma. By contrast, the detection of t(4;14), t(14;16), t(14;20), del17p13, gain 1q, and/or del1p32 are associated with poor prognosis in MM when treated with standard therapy  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 4</a>). The poor outcomes seen in patients with t(4;14) by FISH were shown to be at least partially overcome by therapy that incorporates the early use of bortezomib-containing regimens and hematopoietic cell transplantation (HCT). (See  <a class="medical medical_review" href="/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'High-risk myeloma'</a>.)</p><p>The prognostic value of these chromosomal translocations and deletions detected by FISH analysis has been shown in numerous studies [<a href="#rid20">20-23</a>]. Additional details concerning these abnormalities and their prognostic significance are described in the sections below.</p><p class="headingAnchor" id="H1902473776"><span class="h2">Specific IgH translocations</span><span class="headingEndMark"> — </span>The most common chromosomal translocations in MM involve 14q32, the site of the immunoglobulin heavy chain (IgH) locus and are referred to as "primary IgH translocations." Of these, t(11;14) is the most common. t(4;14) and t(14;16) are considered high-risk cytogenetics in the R-ISS staging system. (See <a class="local">'Revised International Staging System (R-ISS)'</a> above.)</p><p>Primary IgH translocations seen in MM include: </p><p class="bulletIndent1"><span class="glyph">●</span>t(11;14)(q13;q32) </p><p class="bulletIndent1"><span class="glyph">●</span>t(4;14)(p16.3;q32.3) </p><p class="bulletIndent1"><span class="glyph">●</span>t(6;14)(p25;q32)</p><p class="bulletIndent1"><span class="glyph">●</span>t(8;14)(q24;q32)</p><p class="bulletIndent1"><span class="glyph">●</span>t(14;16)(q32.3;q23)</p><p></p><p>These translocations place an oncogene next to the IgH locus such that the active promoter region of the IgH gene induces overexpression of the oncogene. The products of these translocations then act as transcription factors, growth factor receptors, and cell cycle mediators to promote growth and replication. </p><p>t(11;14)(q13;q32) is the most common and defines a subgroup of MM with a particular clinicopathologic phenotype [<a href="#rid24">24</a>]. The incidence of t(11;14) ranges from 10 to 31 percent in patients with IgG, IgA, IgD, and light chain MM [<a href="#rid24">24,25</a>]; it is increased in patients with non-secretory MM (83 percent), as well as in IgM (7 of 8) and IgE (2 of 2) MM [<a href="#rid25">25,26</a>]. Patients with MM and t(11;14) are more likely to have lower levels of serum M proteins and lymphoplasmacytic or small mature plasma cell morphology, CD20 expression, and lambda light chains [<a href="#rid24">24,27-29</a>]. While categorized as "standard risk" disease, patients with t(11;14) have lower response rates and reduced progression-free survival (PFS) and overall survival (OS) than other standard-risk patients [<a href="#rid30">30-34</a>]. (See  <a class="medical medical_review" href="/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology", section on 'Immunoglobulin heavy chain translocations'</a>.)</p><p>The t(4;14), t(14;16), and t(14;20) translocations are associated with poor prognosis [<a href="#rid14">14,20,35</a>]. Of note, while t(4;14) is associated with chemotherapy-sensitive disease, it was previously associated with a high rate of relapse, even in those undergoing high dose chemotherapy followed by autologous HCT [<a href="#rid36">36-38</a>]. While t(4;14) is considered a high-risk genetic abnormality, there is evidence that <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> can overcome the adverse prognosis associated with this finding [<a href="#rid39">39</a>]. </p><p>While not widely available, next-generation sequencing (NGS) can identify prognostically different subsets of MM with t(4;14) based on the coordinates of the translocation breakpoints in the <em>NSD2</em> gene. In a large cohort study that used NGS, median overall survival (OS) differed by breakpoint location [<a href="#rid40">40</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>"Late disruption" - Breakpoint within the <em>NSD2</em> gene downstream of the translation start site (median OS 28.6 months; 31 percent of population)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Early disruption" - Breakpoint between the transcription and translation start site (median OS 59.4 months; 24 percent of population)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"No disruption" - Breakpoint upstream of the <em>NSD2</em> gene (median OS 75.1 months; 45 percent of population) </p><p></p><p>These results were validated in an independent dataset.</p><p>Initial series evaluating the prognostic impact of t(14;16) had mixed results, likely reflecting the small numbers of patients in each cohort due to the rarity of this translocation [<a href="#rid20">20,41,42</a>]. The poor outcomes in patients with t(14;16) were confirmed in an international study that included 223 patients with t(14;16) and reported short median PFS (2.1 years) and OS (4.1 years) [<a href="#rid43">43</a>]. </p><p class="headingAnchor" id="H1902473819"><span class="h2">Del(17p)</span><span class="headingEndMark"> — </span>Deletions of 17p, including 17p13, the <em>TP53</em> gene locus, are found in 10 percent of MM patients and are associated with a shorter survival after both conventional chemotherapy and HCT [<a href="#rid14">14,20,35,44-48</a>]. Del(17p) is considered a high-risk cytogenetic finding in the R-ISS staging system. (See <a class="local">'Revised International Staging System (R-ISS)'</a> above.)</p><p>Del(17p) is highly associated with a low rate of complete response, rapid disease progression, plasma cell leukemia, and central nervous system involvement [<a href="#rid49">49-51</a>]. As an example, a study of 59 patients with previously untreated MM reported that those patients with a <em>TP53</em> gene deletion (present in 33 percent) had shorter median survival (14 versus 39 months from the time of diagnosis) [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology", section on 'Drivers of progression from MGUS to MM'</a>.)</p><p>The presence of mutated <em>TP53</em> on the other allele ("double hit") likely impacts the prognosis of patients with del(17p). One study evaluated patients with uniformly treated newly diagnosed MM for del(17p) and <em>TP53</em> mutations and reported the following PFS and OS outcomes by genetic findings [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Intact 17p (2505 patients) – median PFS 44 months, median OS 152 months </p><p class="bulletIndent1"><span class="glyph">●</span>del(17p) with wild type <em>TP53</em> (76 patients) – median PFS 27.2 months, median OS 52.8 months </p><p class="bulletIndent1"><span class="glyph">●</span>del(17p) with mutated <em>TP53</em> (45 patients) – median PFS 18.1 months, median OS 36 months </p><p></p><p>These results confirm the negative impact of del(17p) on prognosis and identify cases with <em>TP53</em> mutation on the other allele as having a particularly poor prognosis.</p><p class="headingAnchor" id="H615967"><span class="h2">Trisomies</span><span class="headingEndMark"> — </span>Hyperdiploidy is a well-recognized predictor of favorable outcomes in MM. Hyperdiploidy occurs in MM typically due to trisomies of odd numbered chromosomes [<a href="#rid54">54</a>]. </p><p>There are conflicting data on whether the presence of trisomies can ameliorate some of the adverse prognostic effects of high-risk cytogenetic abnormalities [<a href="#rid19">19,55</a>]. We do not downgrade our risk assignment for those with trisomies.</p><p>In one retrospective study of 484 patients with newly diagnosed symptomatic MM, a<strong> </strong>trisomy was present in approximately 60 percent of all patients and 40 percent of patients with high-risk myeloma as defined by FISH showing t(4;14), t(14;16), t(14;20), or loss of p53 [<a href="#rid19">19</a>]. The OS for patients with trisomy in the setting of high-risk MM was similar to that of patients with standard-risk MM defined by FISH. In comparison, patients with high-risk MM without trisomy had shorter survival. </p><p>The impact of trisomy on prognosis may be dependent on the chromosome involved. In another retrospective study of 965 patients with MM, a survival benefit was seen in patients with trisomy 3 and those with trisomy 5, but not in those with trisomy 7, 9, 11, 15, 17, 18, or 19 [<a href="#rid56">56</a>]. In contrast, trisomy 21 was associated with inferior survival.</p><p class="headingAnchor" id="H1902474814"><span class="h2">Other cytogenetic lesions</span><span class="headingEndMark"> — </span>Several other cytogenetic lesions have been associated with adverse prognosis in MM. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chromosome 1 abnormalities</strong> – Abnormalities in both the short and long arms of chromosome 1 have been associated with shorter survival [<a href="#rid57">57-63</a>]. In general, 1q gain (three copies), 1q amplification (four or more copies), and 1p deletion, and 1q21 aberrations are associated with both disease progression and poor prognosis [<a href="#rid57">57,64-70</a>]. As an example, in a study of 1195 patients with MM, chromosome 1p32 deletions were identified in 85 cases (7 percent) and were associated with inferior PFS (14 versus 34 months) and OS (27 versus 97 months) [<a href="#rid61">61</a>]. We consider 1q gain and 1q amplification to be associated with adverse prognosis  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>12p deletions</strong> – Initial studies have suggested that 12p deletions are associated with short event-free survival (EFS) and OS rates, but this needs further confirmation [<a href="#rid60">60</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>MYC</em></strong><strong> rearrangements</strong> – The <em>MYC</em> oncogene is located at 8q24.21. In one series, translocations involving <em>MYC</em> were detected by FISH in 8 percent of newly diagnosed MM [<a href="#rid71">71</a>]. MYC translocations were associated with a higher disease burden and shorter OS. </p><p></p><p class="headingAnchor" id="H2984418976"><span class="h1">DISEASE BIOLOGY</span><span class="headingEndMark"> — </span>In MM, prognosis can be markedly different in patients with similar staging and host factors. These disparities are driven primarily by differences in underlying disease biology, which can greatly influence the aggressiveness of the clinical course. Some of the most important markers of adverse prognosis include atypical bone marrow plasma cell immunophenotype, increased plasma cell proliferative rate, plasmablastic morphology, increased circulating plasma cells, and the presence of extramedullary involvement. </p><p class="headingAnchor" id="H1827881801"><span class="h2">Plasma cell morphology and immunophenotype</span><span class="headingEndMark"> — </span>Plasma cell morphology and immunophenotype may serve as markers for disease aggressiveness. Morphology and immunophenotype more closely resembling normal, reactive plasma cells may be associated with a better prognosis. In contrast, outcomes are worse for patients with MM that exhibits plasmablastic morphology or an atypical immunophenotype.</p><p>A plasmablastic morphology is seen in approximately 8 percent of patients with MM and is associated with highly proliferative disease with shorter event-free survival (EFS) and overall survival (OS) following conventional chemotherapy [<a href="#rid72">72,73</a>]. </p><p>The malignant plasma cells in MM generally express cytoplasmic immunoglobulin, CD38, CD56 (neural cell adhesion molecule), and CD138 [<a href="#rid74">74</a>]. About 15 to 20 percent of patients will have cells that express CD20; such patients are likely to have t(11;14) along with lymphoplasmacytic or small mature plasma cell morphology. Absence of CD56 expression is often seen in plasma cell leukemia [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/6646.html" rel="external">"Plasma cell leukemia", section on 'Prognosis'</a> and <a class="local">'Specific IgH translocations'</a> above.)</p><p>Patients with plasma cells in the bone marrow that demonstrate an immunophenotype resembling normal, reactive plasma cells or a plasma cell immunophenotype generally observed in monoclonal gammopathy of undetermined significance (MGUS) may have a better prognosis when compared with patients whose bone marrow contains plasma cells with an immunophenotype more typical of MM [<a href="#rid76">76-78</a>]. As an example, a prospective series of 685 patients with newly diagnosed MM uniformly treated on protocol found that patients who expressed CD28 or lacked CD117 had significantly shorter progression-free survival (PFS) and OS than patients who expressed CD117 and lacked CD28 [<a href="#rid77">77</a>]. The clinical use of bone marrow plasma cell immunophenotyping studies to help determine prognosis needs further clarification. </p><p class="headingAnchor" id="H3594419544"><span class="h2">Extramedullary disease</span><span class="headingEndMark"> — </span>While uncommon, presentation with or development of extramedullary plasmacytoma, secondary plasma cell leukemia (PCL), or central nervous system (CNS) involvement is associated with worse outcomes [<a href="#rid79">79-84</a>]. </p><p>The true incidence of extramedullary disease at the time of diagnosis is not known. In one large study, extramedullary disease was documented in &lt;5 percent of patients at the time of diagnosis, and at higher rates over the disease course [<a href="#rid79">79</a>]. The most common sites of extramedullary disease were the skin and soft tissue, paraspinal area, lymph nodes, and liver. Other sites of involvement included the kidney, spleen, testes, CNS, and lung. Extracellular disease was more common in MM defined as high risk by gene expression profiling. </p><p>Leptomeningeal myelomatosis along with abnormal cerebrospinal fluid findings is uncommon but denotes a poor prognosis [<a href="#rid50">50,85-89</a>]. It is usually associated with high-risk cytogenetics. Historically, survival in this patient population was measured in months [<a href="#rid88">88</a>], although outcomes appear to be improving since the incorporation of immunomodulatory drugs and proteasome inhibitors into first-line therapy [<a href="#rid83">83,90</a>]. </p><p>The presence of circulating plasma cells is associated with adverse prognosis in MM. The impact differs by the method of detection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Peripheral blood smear</strong> – Patients with MM who have ≥5 percent monoclonal plasma cells on conventional peripheral blood smear meet the diagnostic criteria for plasma cell leukemia (PCL) [<a href="#rid91">91</a>]. Lower levels of circulating plasma cells (eg, 2 to 4 percent) on conventional peripheral smear may also be associated with highly proliferative and aggressive MM [<a href="#rid92">92-94</a>]. PCL is discussed separately. (See  <a class="medical medical_review" href="/d/html/6646.html" rel="external">"Plasma cell leukemia", section on 'Prognosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multicolor flow cytometry</strong> – Circulating plasma cells can be detected by multicolor flow cytometry of the blood in most patients with MM at the time of diagnosis due to the high sensitivity of the assay [<a href="#rid95">95-97</a>]. Several prospective studies have shown that high levels of circulating plasma cells detected by flow cytometry is associated with worse progression-free survival and overall survival independent of other prognostic factors, including the R-ISS [<a href="#rid95">95-97</a>]. Limitations include limited access outside of academic institutions, expense, uncertainty regarding the optimal threshold, and need for a fresh sample. Further studies are also needed to determine the prognostic impact of circulating plasma cells detected by next generation sequencing.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Monoclonal protein</span><span class="headingEndMark"> — </span>The clinical course of MM may be influenced in part by the type of monoclonal (M) protein produced:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with light chain or IgD MM have a higher incidence of renal failure and associated amyloidosis, a smaller serum M-component, and a higher rate of light chain excretion than those with IgG or IgA MM [<a href="#rid98">98,99</a>]. IgD MM typically has a lambda light chain. (See  <a class="medical medical_review" href="/d/html/5589.html" rel="external">"Overview of amyloidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a cryoglobulin (type I cryoglobulinemia) may develop renal disease or other symptoms related to the presence of a cold-insoluble protein. (See  <a class="medical medical_review" href="/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia", section on 'Type I cryoglobulinemia'</a> and  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation", section on 'Less common causes of AKI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is not clear whether the survival of patients with light chain MM is adversely affected. In three large reviews, light chain MM was reported to be not associated with a difference in prognosis [<a href="#rid100">100</a>], or a significant reduction in survival [<a href="#rid8">8</a>]. A significant reduction in survival occurs only if light chain MM is accompanied by renal impairment at presentation [<a href="#rid101">101</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Serum free light chain ratio</span><span class="headingEndMark"> — </span>The serum kappa/lambda free light chain (FLC) assay is a sensitive method for the detection of excess FLCs, and an abnormal kappa/lambda FLC ratio is used as a surrogate marker for clonal expansion. The presence of an abnormal (monoclonal) kappa/lambda FLC ratio in the serum is associated with a higher risk of disease progression in patients with MGUS, solitary plasmacytoma, or smoldering MM. (See  <a class="medical medical_review" href="/d/html/15772.html" rel="external">"Clinical course and management of monoclonal gammopathy of undetermined significance", section on 'Risk stratification to estimate risk of progression'</a>.)</p><p>The FLC ratio may also have prognostic value in patients with newly diagnosed symptomatic MM when used in conjunction with the International Staging System (ISS). As an example, one study evaluated the serum FLC ratio measurement that was available from 790 out of 1027 patients with newly diagnosed MM seen at a large referral center [<a href="#rid102">102</a>]. Patients with abnormal FLC ratio (&lt;0.03 or &gt;32) had a significantly shorter median survival when compared with patients with a FLC ratio between 0.03 and 32 (30 versus 39 months, respectively). Further study is needed to assess impact on patients staged with the revised ISS (R-ISS).</p><p>Further details regarding serum FLC measurement and its use in response assessment is discussed separately. (See  <a class="medical medical_review" href="/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Serum free light chains'</a> and  <a class="medical medical_review" href="/d/html/6648.html" rel="external">"Multiple myeloma: Evaluating response to treatment", section on 'Serum and urine tests'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Gene expression profiling</span><span class="headingEndMark"> — </span>Gene expression profiling (GEP) has been utilized to aid in the discrimination between plasma cells from normal subjects and those with MGUS, MM, AL amyloidosis, and extramedullary plasmacytomas [<a href="#rid59">59,103-109</a>], as well as to identify patients with high-risk myeloma [<a href="#rid110">110-116</a>]. While GEP is not part of the standard risk stratification of patients with MM, patients found to have a high-risk signature on GEP are considered to have high-risk MM on risk stratification  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 4</a>). </p><p>Multiple GEP models are at various stages of development. The following commercially available GEP models have been validated in clinical trials:</p><p class="bulletIndent1"><span class="glyph">●</span>The Myeloma Prognostic Risk Signature (MyPRS) – A 70-gene expression profiling signature developed by the Myeloma Institute for Research and Therapy at Little Rock, Arkansas [<a href="#rid112">112-115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SKY92 Multiple Myeloma Profiler – A 92-gene expression profiling signature developed at Erasmus University Medical Center in the Netherlands [<a href="#rid117">117-119</a>]. </p><p></p><p>This technology, as well as comparative genomic hybridization, whole genome sequencing, tumor-associated antigens, and multiparameter flow cytometry may ultimately have utility for diagnostic, therapeutic, and prognostic purposes [<a href="#rid120">120-128</a>]. Further studies in this area will be necessary to more firmly establish the role of these approaches in management of MM. (See  <a class="medical medical_review" href="/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology"</a>.)</p><p class="headingAnchor" id="H1662883730"><span class="h2">Plasma cell proliferative rate</span><span class="headingEndMark"> — </span>An increased bone marrow plasma cell proliferative rate is associated with adverse prognosis in MM [<a href="#rid129">129-131</a>]. However, plasma cell proliferative rate may not improve risk stratification beyond that calculated based on R-ISS and age [<a href="#rid132">132</a>]. </p><p>Initial methods to measure plasma cell proliferation relied on slide-based immunofluorescence assays, but now proliferation is assessed by measuring the percentage of cells in S phase on flow cytometry.</p><p class="headingAnchor" id="H1245153002"><span class="h1">PATIENT FACTORS</span><span class="headingEndMark"> — </span>The clinical outcome for patients with MM depends on a complex interaction between biologic features of the plasma cell clone and patient-specific factors such as age, performance status, and comorbidities. Patients with comorbidities that limit their ability to withstand treatment will have a poor outcome even if they have MM with features commonly associated with a better prognosis. While much of the research evaluating prognosis in MM has focused on the biologic properties of the malignant clone, large case series have identified numerous prognostic factors, some of which are patient-dependent factors.</p><p>As an example, univariate analysis of a series of 1027 patients with MM seen at the Mayo Clinic between 1985 and 1998 uncovered the following significant adverse prognostic risk factors for survival (relative risks [RR] in parentheses) [<a href="#rid100">100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Performance status 3 or 4  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 5</a>) (1.9)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin &lt;3 g/dL (1.7)</p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥70 years (1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine ≥2 mg/dL (1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count &lt;150,000/microL (1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Beta-2 microglobulin &gt;4 mg/L (1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma cell labeling index ≥1 percent (1.5)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum calcium ≥11 mg/dL (1.3)</p><p class="bulletIndent1"><span class="glyph">●</span>Hemoglobin &lt;10 g/dL (1.3)</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow plasma cell percentage ≥50 percent (1.2)</p><p></p><p>Among these, patient factors such as performance status, albumin concentration, and age appear to have as much or higher prognostic value than many of the disease-related factors.</p><p>Geriatricians commonly measure functional status by evaluating basic activities of daily living (ADLs,  (<a class="graphic graphic_table graphicRef66451" href="/d/graphic/66451.html" rel="external">table 6</a>)), instrumental activities of daily living (IADLs,  (<a class="graphic graphic_table graphicRef63647" href="/d/graphic/63647.html" rel="external">table 7</a>)), and the Charlson comorbidity index (CCI,  (<a class="graphic graphic_table graphicRef72047" href="/d/graphic/72047.html" rel="external">table 8</a>)). ADLs are the skills that are necessary for basic living and include feeding, grooming, transferring, and toileting. IADLs are required to live independently in the community and include activities such as shopping, managing finances, housekeeping, preparing meals, and taking medications. The CCI is a measure of comorbidities. (See  <a class="medical medical_review" href="/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a>.)</p><p>A study by the International Myeloma Working Group used ADLs, IADLs, CCI, and age to quantitate patient frailty in 869 patients with MM (median age 74 years) enrolled on three trials of initial therapy that did not incorporate transplantation [<a href="#rid133">133</a>]. This evaluation discriminated three groups (fit, intermediate frail, frail). When compared with fit patients, frail patients had significantly inferior overall survival (hazard ratio [HR] 3.57), shorter progression-free survival (HR 1.68), higher rates of treatment discontinuation (HR 2.27), and more grade 3/4/5 non-hematologic toxicity (HR 1.74). Prospective studies are needed to better define how these measures can be incorporated into clinical practice.</p><p>Another analysis of 10,549 patients reported that patients older than 50 years had significantly shorter survival when treated with either chemotherapy alone or high dose therapy followed by transplantation [<a href="#rid134">134</a>]. While younger patients tended to present with more favorable features, age at diagnosis itself was an independent predictor of overall survival. A subsequent analysis of the same patient cohort with a median follow-up time of 3.25 years reported mean overall survival times of 6.3, 6.4, 5.3, 4.3, 3.4, and 2.5 years for those patients &lt;40, 40 to 49, 50 to 59, 60 to 69, 70 to 79, and ≥80 years at the time of diagnosis, respectively, indicating that although younger patients have better survival, the number of years of life lost was greater [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H18"><span class="h1">IMAGING STUDIES</span><span class="headingEndMark"> — </span>A discussion of the role of imaging studies in patients with MM and effect on prognosis is presented separately. (See  <a class="medical medical_review" href="/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Imaging'</a>.)</p><p class="headingAnchor" id="H1635143615"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/688.html" rel="external">"Patient education: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1827883253"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heterogeneity of disease</strong> – Multiple myeloma (MM) is a heterogeneous disease; some patients present with rapidly progressive symptoms and organ dysfunction whereas others have a more indolent clinical presentation. Distinction between these groups is important so that treatment can be initiated in appropriate patients and postponed in those who do not need it. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The revised International Staging System (R-ISS)  (<a class="graphic graphic_table graphicRef132695" href="/d/graphic/132695.html" rel="external">table 1</a>) is calculated using serum beta-2 microglobulin, serum albumin, lactate dehydrogenase, and a select group of chromosomal abnormalities detected by fluorescence in situ hybridization (FISH), and it stratifies patients into three risk groups with differing expected disease tempo and overall survival  (<a class="graphic graphic_figure graphicRef105116" href="/d/graphic/105116.html" rel="external">figure 2</a>). (See <a class="local">'Revised International Staging System (R-ISS)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of cytogenetic features</strong> – Due to their prognostic value and the widespread availability of probes for FISH testing, t(4;14), t(14;16), and del17p are considered high-risk cytogenetics in the R-ISS. Other cytogenetic findings consistently associated with poor outcomes include t(14;16) and gain 1q by FISH. (See <a class="local">'Cytogenetic abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease biology</strong> – Differences in disease biology can influence the clinical course and result in markedly different outcomes in patients with similar staging and host factors. Some of the most important markers of adverse prognosis are the atypical bone marrow plasma cell immunophenotype, increased plasma cell proliferative rate, plasmablastic morphology, increased circulating plasma cells, and the presence of extramedullary involvement. (See <a class="local">'Disease biology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of patient factors</strong> – The clinical outcome for patients with MM depends on a complex interaction between biologic features of the plasma cell clone and patient-specific factors such as age, performance status, and comorbidities. Patients with comorbidities that limit their ability to withstand treatment will have a poor outcome even if they have MM with features commonly associated with a better prognosis. (See <a class="local">'Patient factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk stratification for treatment</strong> – Individual cases are stratified into either high-risk or standard-risk MM based on the results of FISH for specific translocations and certain other tests  (<a class="graphic graphic_table graphicRef78344" href="/d/graphic/78344.html" rel="external">table 4</a>). This risk stratification helps to determine prognosis and impacts treatment choice  (<a class="graphic graphic_algorithm graphicRef97453" href="/d/graphic/97453.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management"</a>.)</p><p></p><p class="headingAnchor" id="H1083805851"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges extensive contributions of Robert A Kyle, MD to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Corre J, Perrot A, Hulin C, et al. Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods. Leukemia 2021; 35:3600.</a></li><li><a class="nounderline abstract_t">Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. J Clin Oncol 2020; 38:1928.</a></li><li><a class="nounderline abstract_t">Cote J, Leblanc R, Chu M, et al. Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database. Blood 2022; 140:289.</a></li><li><a class="nounderline abstract_t">Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210.</a></li><li><a class="nounderline abstract_t">Ballman KV. Biomarker: Predictive or Prognostic? J Clin Oncol 2015; 33:3968.</a></li><li><a class="nounderline abstract_t">Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. J Clin Oncol 2021; 39:238.</a></li><li><a class="nounderline abstract_t">Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36:842.</a></li><li><a class="nounderline abstract_t">Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412.</a></li><li><a class="nounderline abstract_t">Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28:269.</a></li><li><a class="nounderline abstract_t">Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33:2863.</a></li><li><a class="nounderline abstract_t">Kastritis E, Terpos E, Roussou M, et al. Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. Haematologica 2017; 102:593.</a></li><li><a class="nounderline abstract_t">González-Calle V, Slack A, Keane N, et al. Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol 2018; 97:1453.</a></li><li><a class="nounderline abstract_t">Jimenez-Zepeda VH, Duggan P, Neri P, et al. Revised International Staging System Applied to Real World Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk 2016; 16:511.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Hulin C, Campion L, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol 2013; 31:2806.</a></li><li><a class="nounderline abstract_t">Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 2016; 127:2955.</a></li><li><a class="nounderline abstract_t">Binder M, Rajkumar SV, Ketterling RP, et al. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J 2017; 7:e600.</a></li><li><a class="nounderline abstract_t">Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.</a></li><li><a class="nounderline abstract_t">Nowakowski GS, Dewald GW, Hoyer JD, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005; 130:36.</a></li><li><a class="nounderline abstract_t">Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012; 119:2100.</a></li><li><a class="nounderline abstract_t">Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569.</a></li><li><a class="nounderline abstract_t">Jacobus SJ, Kumar S, Uno H, et al. Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03. Br J Haematol 2011; 155:340.</a></li><li><a class="nounderline abstract_t">Kapoor P, Fonseca R, Rajkumar SV, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc 2010; 85:532.</a></li><li><a class="nounderline abstract_t">Mateos MV, Gutiérrez NC, Martín-Ramos ML, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance. Blood 2011; 118:4547.</a></li><li><a class="nounderline abstract_t">Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99:3735.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Garand R, Lodé L, et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003; 101:1570.</a></li><li><a class="nounderline abstract_t">Feyler S, O'Connor SJ, Rawstron AC, et al. IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol 2008; 140:547.</a></li><li><a class="nounderline abstract_t">Hoyer JD, Hanson CA, Fonseca R, et al. The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study. Am J Clin Pathol 2000; 113:831.</a></li><li><a class="nounderline abstract_t">Robillard N, Avet-Loiseau H, Garand R, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102:1070.</a></li><li><a class="nounderline abstract_t">Garand R, Avet-Loiseau H, Accard F, et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003; 17:2032.</a></li><li><a class="nounderline abstract_t">Sasaki K, Lu G, Saliba RM, et al. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013; 19:1227.</a></li><li><a class="nounderline abstract_t">Shin HJ, Kim K, Lee JJ, et al. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma. Clin Lymphoma Myeloma Leuk 2015; 15:227.</a></li><li><a class="nounderline abstract_t">Kaufman GP, Gertz MA, Dispenzieri A, et al. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma. Leukemia 2016; 30:633.</a></li><li><a class="nounderline abstract_t">Lakshman A, Alhaj Moustafa M, Rajkumar SV, et al. Natural history of t(11;14) multiple myeloma. Leukemia 2018; 32:131.</a></li><li><a class="nounderline abstract_t">Bal S, Giri S, Godby KN, Costa LJ. Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma. Br J Haematol 2021; 195:e113.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109:3489.</a></li><li><a class="nounderline abstract_t">Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23:7069.</a></li><li><a class="nounderline abstract_t">Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125:64.</a></li><li><a class="nounderline abstract_t">Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106:2837.</a></li><li><a class="nounderline abstract_t">San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.</a></li><li><a class="nounderline abstract_t">Stong N, Ortiz-Estévez M, Towfic F, et al. The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. Blood 2023; 141:1574.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117:2009.</a></li><li><a class="nounderline abstract_t">Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010; 115:4168.</a></li><li><a class="nounderline abstract_t">Goldman-Mazur S, Jurczyszyn A, Castillo JJ, et al. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol 2020; 95:503.</a></li><li><a class="nounderline abstract_t">Drach J, Kaufmann H, Urbauer E, et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126:441.</a></li><li><a class="nounderline abstract_t">Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138:324.</a></li><li><a class="nounderline abstract_t">Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112:4235.</a></li><li><a class="nounderline abstract_t">Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114:522.</a></li><li><a class="nounderline abstract_t">Lakshman A, Painuly U, Rajkumar SV, et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv 2019; 3:1930.</a></li><li><a class="nounderline abstract_t">Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546.</a></li><li><a class="nounderline abstract_t">Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127:280.</a></li><li><a class="nounderline abstract_t">Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22:1250.</a></li><li><a class="nounderline abstract_t">Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92:802.</a></li><li><a class="nounderline abstract_t">Corre J, Perrot A, Caillot D, et al. del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood 2021; 137:1192.</a></li><li><a class="nounderline abstract_t">Smadja NV, Bastard C, Brigaudeau C, et al. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98:2229.</a></li><li><a class="nounderline abstract_t">Pawlyn C, Melchor L, Murison A, et al. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood 2015; 125:831.</a></li><li><a class="nounderline abstract_t">Chretien ML, Corre J, Lauwers-Cances V, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood 2015; 126:2713.</a></li><li><a class="nounderline abstract_t">Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724.</a></li><li><a class="nounderline abstract_t">Debes-Marun CS, Dewald GW, Bryant S, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17:427.</a></li><li><a class="nounderline abstract_t">Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109:2276.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27:4585.</a></li><li><a class="nounderline abstract_t">Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 2014; 28:675.</a></li><li><a class="nounderline abstract_t">Caltagirone S, Ruggeri M, Aschero S, et al. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica 2014; 99:1611.</a></li><li><a class="nounderline abstract_t">Croft J, Ellis S, Sherborne AL, et al. Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia 2020.</a></li><li><a class="nounderline abstract_t">Hebraud B, Magrangeas F, Cleynen A, et al. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. Blood 2015; 125:2095.</a></li><li><a class="nounderline abstract_t">Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 2020; 4:3509.</a></li><li><a class="nounderline abstract_t">Giri S, Huntington SF, Wang R, et al. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv 2020; 4:2245.</a></li><li><a class="nounderline abstract_t">Kastritis E, Migkou M, Dalampira D, et al. Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications. Am J Hematol 2022; 97:1142.</a></li><li><a class="nounderline abstract_t">Schavgoulidze A, Talbot A, Perrot A, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood 2023; 141:1308.</a></li><li><a class="nounderline abstract_t">Mohan M, Gong Z, Ashby TC, et al. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer 2023; 129:2491.</a></li><li><a class="nounderline abstract_t">Wang Y, Xu J, Xu B, et al. The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse. Cancer 2023; 129:1005.</a></li><li><a class="nounderline abstract_t">Abdallah N, Baughn LB, Rajkumar SV, et al. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res 2020; 26:6581.</a></li><li><a class="nounderline abstract_t">Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91:2501.</a></li><li><a class="nounderline abstract_t">Møller HE, Preiss BS, Pedersen P, et al. Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. APMIS 2015; 123:652.</a></li><li><a class="nounderline abstract_t">Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100:3095.</a></li><li class="breakAll">Grogan TM, Van Camp B, Kyle RA. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardinman JW (Eds), IARC Press, Lyon 2001. p.142.</li><li><a class="nounderline abstract_t">Paiva B, Vidriales MB, Mateo G, et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009; 114:4369.</a></li><li><a class="nounderline abstract_t">Mateo G, Montalbán MA, Vidriales MB, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26:2737.</a></li><li><a class="nounderline abstract_t">Burgos L, Tamariz-Amador LE, Puig N, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol 2023; 41:3019.</a></li><li><a class="nounderline abstract_t">Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica 2012; 97:1761.</a></li><li><a class="nounderline abstract_t">Jurczyszyn A, Castillo JJ, Avivi I, et al. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma 2019; 60:118.</a></li><li><a class="nounderline abstract_t">Avivi I, Cohen YC, Suska A, et al. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol 2019; 94:1132.</a></li><li><a class="nounderline abstract_t">Jun BK, Ho B, Yuen T. Intracranial multiple myeloma with intraparenchymal involvement: Case report and literature review. J Clin Neurosci 2019; 59:335.</a></li><li><a class="nounderline abstract_t">Gozzetti A, Cerase A, Lotti F, et al. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer 2012; 118:1574.</a></li><li><a class="nounderline abstract_t">Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21:325.</a></li><li><a class="nounderline abstract_t">Petersen SL, Wagner A, Gimsing P. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature. Am J Hematol 1999; 62:228.</a></li><li><a class="nounderline abstract_t">Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol 2002; 117:103.</a></li><li><a class="nounderline abstract_t">Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. Arch Neurol 2004; 61:1423.</a></li><li><a class="nounderline abstract_t">Chamberlain MC, Glantz M. Myelomatous meningitis. Cancer 2008; 112:1562.</a></li><li><a class="nounderline abstract_t">Lee D, Kalff A, Low M, et al. Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. Br J Haematol 2013; 162:371.</a></li><li><a class="nounderline abstract_t">Chen CI, Masih-Khan E, Jiang H, et al. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol 2013; 162:483.</a></li><li><a class="nounderline abstract_t">Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 2021; 11:192.</a></li><li><a class="nounderline abstract_t">Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J 2018; 8:116.</a></li><li><a class="nounderline abstract_t">An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol 2015; 94:257.</a></li><li><a class="nounderline abstract_t">Jelinek T, Bezdekova R, Zihala D, et al. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol 2023; 41:1383.</a></li><li><a class="nounderline abstract_t">Bertamini L, Oliva S, Rota-Scalabrini D, et al. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol 2022; 40:3120.</a></li><li><a class="nounderline abstract_t">Hofste Op Bruinink D, Kuiper R, van Duin M, et al. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol 2022; 40:3132.</a></li><li><a class="nounderline abstract_t">Garcés JJ, Cedena MT, Puig N, et al. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. J Clin Oncol 2022; 40:3151.</a></li><li><a class="nounderline abstract_t">Bladé J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12:2398.</a></li><li><a class="nounderline abstract_t">Kim MK, Suh C, Lee DH, et al. Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. Ann Oncol 2011; 22:411.</a></li><li><a class="nounderline abstract_t">Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.</a></li><li><a class="nounderline abstract_t">Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood 2006; 108:2013.</a></li><li><a class="nounderline abstract_t">Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22:1933.</a></li><li><a class="nounderline abstract_t">Tarte K, Zhan F, De Vos J, et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood 2003; 102:592.</a></li><li><a class="nounderline abstract_t">Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood 2002; 100:2175.</a></li><li><a class="nounderline abstract_t">Zhan F, Tian E, Bumm K, et al. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003; 101:1128.</a></li><li><a class="nounderline abstract_t">Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101:4998.</a></li><li><a class="nounderline abstract_t">Hedvat CV, Comenzo RL, Teruya-Feldstein J, et al. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 2003; 122:728.</a></li><li><a class="nounderline abstract_t">Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003; 102:4504.</a></li><li><a class="nounderline abstract_t">Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105:794.</a></li><li><a class="nounderline abstract_t">Dring AM, Davies FE, Fenton JA, et al. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res 2004; 10:5692.</a></li><li><a class="nounderline abstract_t">Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008; 26:4798.</a></li><li><a class="nounderline abstract_t">Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009; 23:1941.</a></li><li><a class="nounderline abstract_t">Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13:7073.</a></li><li><a class="nounderline abstract_t">Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116:2543.</a></li><li><a class="nounderline abstract_t">Kumar SK, Uno H, Jacobus SJ, et al. Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2011; 118:4359.</a></li><li><a class="nounderline abstract_t">Kuiper R, van Duin M, van Vliet MH, et al. Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015; 126:1996.</a></li><li><a class="nounderline abstract_t">van Beers EH, van Vliet MH, Kuiper R, et al. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2017; 17:555.</a></li><li><a class="nounderline abstract_t">Shah V, Sherborne AL, Johnson DC, et al. Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia 2020; 34:3091.</a></li><li><a class="nounderline abstract_t">Kuiper R, Broyl A, de Knegt Y, et al. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26:2406.</a></li><li><a class="nounderline abstract_t">Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol 2003; 120:3.</a></li><li><a class="nounderline abstract_t">Gutiérrez NC, García JL, Hernández JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104:2661.</a></li><li><a class="nounderline abstract_t">Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106:1021.</a></li><li><a class="nounderline abstract_t">Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020.</a></li><li><a class="nounderline abstract_t">Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007; 109:1692.</a></li><li><a class="nounderline abstract_t">Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110:2586.</a></li><li><a class="nounderline abstract_t">Nair B, Shaughnessy JD Jr, Zhou Y, et al. Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood 2009; 113:6572.</a></li><li><a class="nounderline abstract_t">Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009; 27:4197.</a></li><li><a class="nounderline abstract_t">Samur MK, Aktas Samur A, Fulciniti M, et al. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol 2020; 38:3107.</a></li><li><a class="nounderline abstract_t">Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81:3382.</a></li><li><a class="nounderline abstract_t">Larsen JT, Chee CE, Lust JA, et al. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood 2011; 118:2702.</a></li><li><a class="nounderline abstract_t">Aljama MA, Sidiqi MH, Lakshman A, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv 2018; 2:3149.</a></li><li><a class="nounderline abstract_t">Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv 2020; 4:2236.</a></li><li><a class="nounderline abstract_t">Palumbo A, Bringhen S, Mateos MV, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015; 125:2068.</a></li><li><a class="nounderline abstract_t">Ludwig H, Durie BG, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008; 111:4039.</a></li><li><a class="nounderline abstract_t">Ludwig H, Bolejack V, Crowley J, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28:1599.</a></li></ol></div><div id="topicVersionRevision">Topic 6658 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34099876" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298201" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19798094" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26392104" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biomarker: Predictive or Prognostic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326253" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1182674" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809451" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : International staging system for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974982" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : IMWG consensus on risk stratification in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240224" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789676" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29623394" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27425179" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Revised International Staging System Applied to Real World Multiple Myeloma Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796999" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002115" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28862698" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11990854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multiple myeloma: evolving genetic events and host interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982342" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234687" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576322" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical and biologic implications of recurrent genomic aberrations in myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902684" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511484" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21900193" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986230" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393502" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18275432" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10874884" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12702507" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14513054" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733001" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25812994" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487275" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28655925" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Natural history of t(11;14) multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34165783" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17209057" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129840" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15015970" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15976175" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753647" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35984902" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20962323" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124509" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32072687" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10961386" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The biology of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17555471" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337559" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19332768" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31248884" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Impact of acquired del(17p) in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14989251" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Genetics and cytogenetics of multiple myeloma: a workshop report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15491286" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18418408" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9680348" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33080624" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568011" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Hypodiploidy is a major prognostic factor in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25428216" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26516228" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705089" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592343" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105813" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687334" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Prognostic significance of copy-number alterations in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892719" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015938" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636340" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750129" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442299" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35731917" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36375118" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37282609" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36704927" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33008815" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516151" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26152595" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384404" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384404" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755674" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443352" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36930848" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689675" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29965787" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334859" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442452" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intracranial multiple myeloma with intraparenchymal involvement: Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21932386" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633044" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589078" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11918539" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364689" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Multiple myeloma invasion of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18260094" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Myelomatous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718539" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23772701" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34857730" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442928" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25231928" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36315921" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35666982" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35357885" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35666958" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964956" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20682550" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12528874" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Review of 1027 patients with newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728700" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18596742" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663452" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12200383" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A molecular compendium of genes expressed in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12393520" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12623842" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930383" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947006" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388584" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355895" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591550" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19657360" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The molecular characterization and clinical management of multiple myeloma in the post-genome era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18056185" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20574050" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860025" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26330243" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28735890" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157174" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722715" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : A gene expression signature for high-risk multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492570" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Tumour-associated antigens in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238415" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827134" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16728703" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The molecular classification of multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17023574" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17576818" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19389881" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19636021" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687451" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8507875" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750316" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30463914" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32442300" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25628469" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18268097" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177027" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Survival and years of life lost in different age cohorts of patients with multiple myeloma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
